Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serotonin 5-hydroxytryptamine receptor 3 (5-HT3) is a ligand-gated ion channel that mediates fast excitatory neurotransmission in both the central and peripheral nervous systems by allowing cation influx upon activation by serotonin (5-HT). It is a pentameric complex, with both homopentameric (5-HT3A subunits only) and heteropentameric (e.g., 5-HT3A with 5-HT3B) forms. Activation leads to Na⁺ and K⁺ influx, causing neuronal depolarization/excitation and triggering neurotransmitter release. Clinically important antagonists like ondansetron and granisetron are used as antiemetics.
Blocks vagal afferent signaling from gut enterochromaffin cells via inhibition of this receptor subtype.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin 5-hydroxytryptamine receptor 3 (5-HT3).